Search

Displaying results 4661 - 4670 of 10000 in total
  1. Drug

    Demegestone

    go.drugbank.com/drugs/DB13857
    Experimental

    Demegestone is a progesterone receptor agonist that was previously used to treat luteal insufficiency. It was previously marketed in France as Lutionex, but has since been discontinued.

    Categories: Sex Hormones and Modulators of the Genital System
  2. Drug

    Cyclizine

    go.drugbank.com/drugs/DB01176
    ApprovedWithdrawn

    A histamine H1 antagonist given by mouth or parenterally for the control of postoperative and drug-induced vomiting and in motion sickness. (From Martindale, The Extra Pharmacopoeia, 30th ed, p935)

  3. Drug

    Taurochenodeoxycholic acid

    go.drugbank.com/drugs/DB08833
    Experimental

    As a medication, taurochenodeoxycholic acid reduces cholesterol formation in the liver, and is likely used as a choleretic to increase the volume of bile secretion from the liver and as a cholagogue to … Taurochenodeoxycholic acid is an experimental drug that is normally produced in the liver. Its physiologic function is to emulsify lipids such as cholesterol in the bile.

  4. Drug

    Cilomilast

    go.drugbank.com/drugs/DB03849
    Investigational

    Following four clinical trials, the drug proved to be effective in treating COPD, however it has never been marketed due to a poor side effect profile. … Cilomilast (Ariflo, SB-207,499) is a drug which was developed for the treatment of respiratory disorders such as asthma and Chronic Obstructive Pulmonary Disease (COPD).

  5. Drug

    Suvecaltamide

    go.drugbank.com/drugs/DB19139
    Investigational

    Suvecaltamide is under investigation in clinical trial NCT05122650 (A Study to Assess the Safety and Efficacy of JZP385 in the Treatment of Adults With Moderate to Severe Essential Tremor (ET)).

  6. Drug

    Methylprednisolone

    go.drugbank.com/drugs/DB00959
    ApprovedInvestigationalVet approved

    [A188811] It was first described in the literature in the late 1950s.[A188811,A188814] Methylprednisolone was granted FDA approval on 24 October 1957. … [A192813] The efficacy of methylprednisolone in novel coronavirus pneumonia is being investigated further in clinical trials.[L12666]

    Categories: Corticosteroid Hormone Receptor AgonistsProducts: DE SOLUCIÓN INYECTABLE.I.M.. I.V. LENTA . NFUSIÓN I.V.
  7. Drug

    Letermovir

    go.drugbank.com/drugs/DB12070
    ApprovedInvestigational

    It is currently marketed under the brand name Prevymis.[L1021] … [L1021] It is the first of a new class of CMV anti-infectives called DNA terminase complex inhibitors.[A31290] Letermovir has recieved both priority and orphan drug status from the FDA.

  8. Target

    Mitochondrial potassium channel ATP-binding subunit

    go.drugbank.com/bio_entities/BE0003673
    TransporterHumans

    ATP-binding subunit of the mitochondrial ATP-gated potassium channel (mitoK(ATP)) (PubMed:31435016). Together with pore-forming subunit CCDC51/MITOK of the mitoK(ATP) channel, mediates ATP-dependent potassium currents across the mitochon...

    Synonyms: Mitochondrial sulfonylurea-receptor
  9. Drug

    Temanogrel

    go.drugbank.com/drugs/DB05227
    Investigational

    APD791 is intended to lower the risk of arterial thrombosis by reducing the amplification of platelet aggregation, arterial constriction and intimal hyperplasia mediated by serotonin.

    Categories: Serotonin Receptor Antagonists, Serotonin 5-HT2 Receptor Antagonists
  10. Drug

    PF-03187207

    go.drugbank.com/drugs/DB05746
    Investigational

    The development of abnormally high IOP, due to blockage or malfunction of systems controlling the amount of fluid in the eye, is believed to be one of the principal causes of glaucoma. … Based on the very promising preclinical results and on the well-known activities of nitric oxide, PF-03187207 is expected to have an increased capacity to reduce high IOP.